Merck & Company, Inc. (MRK)
Latest news, insights and market data
Market Data
AI Insights
Merck's Keytruda is facing a patent cliff, which could impact its status as the top-selling cancer treatment. The company is working on new therapies, including antibody-drug conjugates and bispecific antibodies, to maintain its competitive edge in the oncology market. As competition increases, how well these new drugs perform will be crucial for Merck's future revenue.
Latest News
| Title | Published |
|---|---|
Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer | about 5 hours ago |
Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over. Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over. | about 17 hours ago |
Merck (MRK) Declines More Than Market: Some Information for Investors Merck (MRK) Declines More Than Market: Some Information for Investors | about 18 hours ago |
Merck (MRK) Declines More Than Market: Some Information for Investors Merck (MRK) concluded the recent trading session at $124.4, signifying a -2.43% move from its prior day's close. | about 18 hours ago |
Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive | about 19 hours ago |
Stay informed with the top movers within the dow jones index on Monday. Curious about the top performers within the dow jones index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. | about 20 hours ago |
Reading Between The Lines Of JNJ Stock's Latest Call Reading Between The Lines Of JNJ Stock's Latest Call | about 21 hours ago |
Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer
Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer
Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.
Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.
Merck (MRK) Declines More Than Market: Some Information for Investors
Merck (MRK) Declines More Than Market: Some Information for Investors
Merck (MRK) Declines More Than Market: Some Information for Investors
Merck (MRK) concluded the recent trading session at $124.4, signifying a -2.43% move from its prior day's close.
Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
Stay informed with the top movers within the dow jones index on Monday.
Curious about the top performers within the dow jones index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Reading Between The Lines Of JNJ Stock's Latest Call
Reading Between The Lines Of JNJ Stock's Latest Call